Analyst Charles Rhyee of TD Cowen maintained a Hold rating on Icon, reducing the price target to $172.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Rhyee has given his Hold rating due to a combination of factors impacting Icon’s financial outlook. The company is expected to face ongoing margin pressure from increased pass-through costs, which are anticipated to persist into the fourth quarter and the following year. Additionally, pricing challenges due to market competition have not yet been fully realized, posing further risks to the company’s margins in 2026.
Elevated cancellation rates are another concern, with expectations that these will continue into the fourth quarter and potentially extend into 2026, affecting revenue growth. The anticipated revenue growth for 2026 appears optimistic, with Rhyee projecting a potential year-over-year decline. These combined pressures on revenue and margins suggest a challenging setup for Icon in 2026, justifying the Hold rating.
According to TipRanks, Rhyee is a 3-star analyst with an average return of 2.4% and a 48.51% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as CVS Health, Evolent Health, and GoodRx Holdings.
In another report released yesterday, Barclays also maintained a Hold rating on the stock with a $190.00 price target.